Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03323944 · ClinicalTrials.gov registry record · Phase 1
CAR T Cell Immunotherapy for Pancreatic Cancer
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT03323944: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT03323944 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03323944, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
Phase I study to establish the safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells in patients with histologically confirmed unresectable or metastatic pancreatic adenocarcinoma
Interventions
- BIOLOGICAL huCART-meso cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-09-15 |
| Est. Completion | 2025-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03323944
The ClinicalTrials.gov registry entry for NCT03323944 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which huCART-meso cells is the first listed.
NCT03323944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03323944 about?
NCT03323944 is a clinical study titled "CAR T Cell Immunotherapy for Pancreatic Cancer". Phase I study to establish the safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells in patients with histologically confirmed unresectable or metastatic pancreatic adenocarcinoma
What is the current status of trial NCT03323944?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2017-09-15. Estimated completion is 2025-02-20.
What interventions are being tested in trial NCT03323944?
The interventions under investigation include: huCART-meso cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03323944?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.